AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11430325 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 1202
Study 9429379 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous blood transfusion
Number of subjects: 50
Study 9429379 — intervention group
Group type: COMPARATOR
Intervention: Homologous blood transfusion
Number of subjects: 50
Study 8504634 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation (4 x 5 g of creatine plus 1 g of glucose/day)
Number of subjects: 12
Study 8504634 — intervention group
Group type: COMPARATOR
Intervention: Placebo (4 x 6 g of glucose/day)
Number of subjects: 12
Study 8504634 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation
Number of subjects: 12
Study 8504634 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 3114788 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam 1 mg
Number of subjects: 45
Study 3114788 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam 2 mg
Number of subjects: 45
Study 3114788 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxazepam 15 mg
Number of subjects: 45
Study 3114788 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxazepam 30 mg
Number of subjects: 45
Study 3114788 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 30277951 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich fibrin (PRF)
Number of subjects: 20
Study 30277951 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PRF)
Number of subjects: 20
Study 27779482 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg of alprazolam orally one hour before the procedure
Number of subjects: 50
Study 27779482 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 25404102 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray (200 µg daily for 8 weeks, then 200 µg on alternate days for 16 weeks)
Number of subjects: 100
Study 25404102 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray
Number of subjects: 100
Study 25404102 — intervention group
Group type: COMPARATOR
Intervention: Saline nasal spray (control)
Number of subjects: 100
Study 23239871 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower body negative pressure (LBNP) applied during the second trial to heighten sympathetic nerve activity.
Number of subjects: 0
Study 23239871 — intervention group
Group type: COMPARATOR
Intervention: Control group with no alteration in sympathetic nerve activity between trials.
Number of subjects: 0
Study 20083626 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed infusions of levosimendan (6 h administration at 0.2 microg/kg/min every 2 weeks)
Number of subjects: 120
Study 20083626 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed infusions of levosimendan
Number of subjects: 120
Study 20083626 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 120
Study 18456697 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrostomy placement
Number of subjects: 76
Study 16130187 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium
Number of subjects: 20
Study 16130187 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium
Number of subjects: 20
Study 12151930 — intervention group
Group type: EXPERIMENTAL
Intervention: NOx.5 l (oxygen-nitrous oxide, MFA after 10 min high fresh gas flow)
Number of subjects: 56
Study 12151930 — intervention group
Group type: COMPARATOR
Intervention: Ox.5 l (oxygen, MFA)
Number of subjects: 56
Study 12151930 — intervention group
Group type: COMPARATOR
Intervention: Ox1 l (oxygen, LFA)
Number of subjects: 56
Study 12151930 — intervention group
Group type: EXPERIMENTAL
Intervention: NOx1 l (oxygen-nitrous oxide, LFA after 10 min high fresh gas flow)
Number of subjects: 56
Study 10417507 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline infusion into the brachial artery at a rate of 2 ml/100 ml forearm min‐1
Number of subjects: 9
Study 10417507 — intervention group
Group type: COMPARATOR
Intervention: Control (no saline infusion)
Number of subjects: 9
Study 8771259 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepitel (silicone rubber dressing)
Number of subjects: 0
Study 8771259 — intervention group
Group type: COMPARATOR
Intervention: Paraffin gauze (control)
Number of subjects: 0
Study 1974401 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine, 10 mg once daily
Number of subjects: 16
Study 1974401 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 7305608 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine hydrochloride, peak mean dose of 16 micro g/kg/day, administered for 10 to 11 days
Number of subjects: 25
Study 7305608 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine hydrochloride
Number of subjects: 25
Study 30227423 — intervention group
Group type: EXPERIMENTAL
Intervention: H2‐O2 (6 L per min, H2:O2 = 2: 1) for 15 min
Number of subjects: 35
Study 30227423 — intervention group
Group type: COMPARATOR
Intervention: O2 (3 L per min) for 15 min
Number of subjects: 35
Study 30227423 — intervention group
Group type: COMPARATOR
Intervention: Air for 15 min
Number of subjects: 35
Study 27082841 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional Processing Writing (EPW)
Number of subjects: 98
Study 27082841 — intervention group
Group type: COMPARATOR
Intervention: Fact Control Writing (FCW)
Number of subjects: 98
Study 23688140 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-session evidence-based family-school intervention
Number of subjects: 92
Study 24611442 — intervention group
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 10-100 mg/day (children) or 25-200 mg/day (adolescents) for 8 months
Number of subjects: 40
Study 22700995 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganitumab (12 mg/kg every 2 weeks) combined with gemcitabine (1000 mg/m2 on days 1, 8, and 15 of each 28-day cycle)
Number of subjects: 125
Study 22700995 — intervention group
Group type: EXPERIMENTAL
Intervention: Conatumumab (10 mg/kg every 2 weeks) combined with gemcitabine (1000 mg/m2 on days 1, 8, and 15 of each 28-day cycle)
Number of subjects: 125
Study 22700995 — intervention group
Group type: COMPARATOR
Intervention: Placebo combined with gemcitabine (1000 mg/m2 on days 1, 8, and 15 of each 28-day cycle)
Number of subjects: 125
Study 17950944 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk-based multifactorial fall prevention program
Number of subjects: 591
Study 17950944 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 591
Study 16834658 — intervention group
Group type: EXPERIMENTAL
Intervention: Proliferating cell nuclear antigen labeling index (PCNA LI)
Number of subjects: 60
Study 16834658 — intervention group
Group type: EXPERIMENTAL
Intervention: PCNA LI of 20 or more
Number of subjects: 60
Study 16834658 — intervention group
Group type: COMPARATOR
Intervention: PCNA LI of less than 20
Number of subjects: 60
Study 13129985 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (600 mg/d for 3 days during week 1, then 600 mg/wk during weeks 2‐12; n = 3879)
Number of subjects: 7747
Study 13129985 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 3868)
Number of subjects: 7747
Study 13129985 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 7747
Study 13129985 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7747
Study 10373219 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitors (ACE-I)
Number of subjects: 16
Study 10373219 — intervention group
Group type: COMPARATOR
Intervention: Control (heparin)
Number of subjects: 16
Study 8763897 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional fractionation (CF) - 70 Gy in 35 fractions over 7 weeks
Number of subjects: 90
Study 8763897 — intervention group
Group type: EXPERIMENTAL
Intervention: Vienna-CHART - 55.3 Gy in 33 fractions within 17 consecutive days
Number of subjects: 90
Study 8763897 — intervention group
Group type: EXPERIMENTAL
Intervention: Vienna-CHART + MMC - 55.3 Gy in 33 fractions within 17 consecutive days with mitomycin C on day 5
Number of subjects: 90
Study 1983848 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic epinephrine injection
Number of subjects: 132
Study 1983848 — intervention group
Group type: COMPARATOR
Intervention: Heat probe treatment
Number of subjects: 132
Study 6836750 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant hormone therapy (gestonorone caproate, 200 mg/week for 1 year)
Number of subjects: 62
Study 6836750 — intervention group
Group type: COMPARATOR
Intervention: No further treatment (control group)
Number of subjects: 62
Study 6836750 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant hormone therapy
Number of subjects: 62
Study 30470892 — intervention group
Group type: EXPERIMENTAL
Intervention: Myofascial release treatment (MR)
Number of subjects: 24
Study 30470892 — intervention group
Group type: COMPARATOR
Intervention: Placebo manual lymphatic drainage treatment (PMLD)
Number of subjects: 24
Study 30470892 — intervention group
Group type: COMPARATOR
Intervention: Both therapies
Number of subjects: 24
Study 29744966 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-Book© art therapy
Number of subjects: 60
Study 29744966 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 60
Study 26559447 — intervention group
Group type: COMPARATOR
Intervention: Normobaric normoxia (NN)
Number of subjects: 3
Study 26559447 — intervention group
Group type: EXPERIMENTAL
Intervention: Normobaric hypoxia (NH)
Number of subjects: 3
Study 26559447 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypobaric hypoxia (HH)
Number of subjects: 3
Study 24440325 — intervention group
Group type: EXPERIMENTAL
Intervention: None-to-mild target lesion calcium
Number of subjects: 6855
Study 24440325 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate target lesion calcium
Number of subjects: 6855
Study 24440325 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe target lesion calcium
Number of subjects: 6855
Study 24440325 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe calcium presence
Number of subjects: 6855
Study 22695903 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid 500 mg twice daily
Number of subjects: 125
Study 22695903 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study 22695903 — intervention group
Group type: EXPERIMENTAL
Intervention: Early term delivery
Number of subjects: 125
Study 22695903 — intervention group
Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 125
Study 20577914 — intervention group
Group type: EXPERIMENTAL
Intervention: Medial-to-lateral laparoscopic right hemi-colectomy (Group M)
Number of subjects: 48
Study 20577914 — intervention group
Group type: COMPARATOR
Intervention: Lateral-to-medial laparoscopic right hemi-colectomy (Group L)
Number of subjects: 48
Study 17379431 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive chemotherapy regimens (MACOP-B/VACOP-B) plus involved field radiotherapy (IFRT)
Number of subjects: 53
Study 17379431 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy (HD-CT) followed by IFRT
Number of subjects: 53
Study 17379431 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy (HD-CT)
Number of subjects: 53
Study 17379431 — intervention group
Group type: EXPERIMENTAL
Intervention: No further treatment
Number of subjects: 53
Study 15679751 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly telephone monitoring and counseling combined with a support group in the first 4 weeks (TEL)
Number of subjects: 359
Study 15679751 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-weekly standard group counseling (STND)
Number of subjects: 359
Study 15679751 — intervention group
Group type: COMPARATOR
Intervention: Twice-weekly individualized relapse prevention (RP)
Number of subjects: 359
Study 12162978 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhys‐Davies exsanguinator alone
Number of subjects: 100
Study 12162978 — intervention group
Group type: COMPARATOR
Intervention: Rhys‐Davies exsanguinator supplemented by a 500 ml bag of intravenous fluid
Number of subjects: 100
Study 9549710 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (Group 3) - coordination and balance training, 3 days per week, 10 minutes each day for 6 weeks
Number of subjects: 45
Study 9549710 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group 1)
Number of subjects: 45
Study 9549710 — intervention group
Group type: COMPARATOR
Intervention: Sham group (Group 2)
Number of subjects: 45
Study 7892154 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-negative group
Number of subjects: 200
Study 7892154 — intervention group
Group type: COMPARATOR
Intervention: HIV-positive group
Number of subjects: 200
Study 2361795 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose prednisolone (120 mg/day)
Number of subjects: 22
Study 2361795 — intervention group
Group type: COMPARATOR
Intervention: Low-dose prednisolone (60 mg/day)
Number of subjects: 22
Study 24618 — intervention group
Group type: EXPERIMENTAL
Intervention: Valium
Number of subjects: 0
Study 24618 — intervention group
Group type: EXPERIMENTAL
Intervention: Serax
Number of subjects: 0
Study 24618 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 30741001 — intervention group
Group type: EXPERIMENTAL
Intervention: Messages communicating comparative risk of e‐cigarettes and combusted cigarettes
Number of subjects: 1202
Study 27161892 — intervention group
Group type: EXPERIMENTAL
Intervention: Peptide-based, high Protein, high omega‐3 fat (Vital AF®, Abbott Nutrition)
Number of subjects: 49
Study 27161892 — intervention group
Group type: COMPARATOR
Intervention: High protein standard enteral formula (Osmolite®, Abbott Nutrition)
Number of subjects: 49
Study 25732758 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mm pen needle
Number of subjects: 66
Study 25732758 — intervention group
Group type: COMPARATOR
Intervention: 8 mm pen needle
Number of subjects: 66
Study 23547487 — intervention group
Group type: EXPERIMENTAL
Intervention: Powered toothbrush (Spinbrush GLOBRUSH)
Number of subjects: 105
Study 23547487 — intervention group
Group type: COMPARATOR
Intervention: Manual toothbrush (Oral-B Indicator 30 Compact Soft Toothbrush)
Number of subjects: 105
Study 21454149 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% C‐β‐D‐xylopyranoside‐2‐hydroxy‐propane (C‐xyloside) cream
Number of subjects: 5
Study 21454149 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 19490299 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive discharge planning
Number of subjects: 50
Study 19490299 — intervention group
Group type: COMPARATOR
Intervention: Routine discharge nursing care
Number of subjects: 50
Study 17016596 — intervention group
Group type: EXPERIMENTAL
Intervention: CKLQ (Cobrotoxin, tramadol hydrochloride, ibuprofen)
Number of subjects: 230
Study 17016596 — intervention group
Group type: COMPARATOR
Intervention: Tramadol hydrochloride
Number of subjects: 230
Study 17016596 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 230
Study 17016596 — intervention group
Group type: EXPERIMENTAL
Intervention: CKLQ
Number of subjects: 230
Study 14519830 — intervention group
Group type: EXPERIMENTAL
Intervention: Decaffeinated green tea (4 cups/day)
Number of subjects: 143
Study 14519830 — intervention group
Group type: EXPERIMENTAL
Intervention: Decaffeinated black tea (4 cups/day)
Number of subjects: 143
Study 14519830 — intervention group
Group type: COMPARATOR
Intervention: Water (control group)
Number of subjects: 143
Study 10782811 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 20
Study 10782811 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenidap
Number of subjects: 20
Study 10782811 — intervention group
Group type: EXPERIMENTAL
Intervention: Early changes in MMP‐3 levels
Number of subjects: 20
Study 8636192 — intervention group
Group type: EXPERIMENTAL
Intervention: Tubular bandage and crutches
Number of subjects: 45
Study 8636192 — intervention group
Group type: COMPARATOR
Intervention: Plaster-of-Paris cast
Number of subjects: 45
Study 1418362 — intervention group
Group type: EXPERIMENTAL
Intervention: Velnacrine 300 mg/day
Number of subjects: 0
Study 1418362 — intervention group
Group type: EXPERIMENTAL
Intervention: Velnacrine 225 mg/day
Number of subjects: 0
Study 6691478 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurazepam
Number of subjects: 14
Study 6691478 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxazepam
Number of subjects: 14
Study 31481453 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT)
Number of subjects: 990
Study 31481453 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (CT)
Number of subjects: 990
Study 31481453 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiation (CRT)
Number of subjects: 990
Study 31481453 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT) for stage IIIC
Number of subjects: 990
Study 31481453 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (CT) for stage IIIC
Number of subjects: 990
Study 31481453 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiation (CRT) for stage IIIC
Number of subjects: 990
Study 30368249 — intervention group
Group type: COMPARATOR
Intervention: 0.1% CHX solution (control group)
Number of subjects: 150
Study 30368249 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum 299 (Lp299)
Number of subjects: 150
Study 26920601 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab (140 mg subcutaneously every 2 weeks or 420 mg subcutaneously every month)
Number of subjects: 27564
Study 26920601 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo injections
Number of subjects: 27564
Study 26920601 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab
Number of subjects: 27564
Study 25222893 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal decolonization with mupirocin and chlorhexidine (CHG) bathing
Number of subjects: 9878
Study 25222893 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted decolonization (screening, isolation, and decolonization of MRSA carriers)
Number of subjects: 9878
Study 25222893 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening and isolation (MRSA nares screening and isolation)
Number of subjects: 9878
Study 25222893 — intervention group
Group type: COMPARATOR
Intervention: Comparison of all arms
Number of subjects: 9878
Study 23207160 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin receptor blockers (ARB) - candesartan
Number of subjects: 120
Study 23207160 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers - metoprolol
Number of subjects: 120
Study 23207160 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ARB and beta-blockers
Number of subjects: 120
Study 23207160 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 20708813 — intervention group
Group type: EXPERIMENTAL
Intervention: AST-120
Number of subjects: 0
Study 20708813 — intervention group
Group type: COMPARATOR
Intervention: Control strategy
Number of subjects: 0
Study 17062657 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-weekly strength training (1 day/week)
Number of subjects: 18
Study 17062657 — intervention group
Group type: COMPARATOR
Intervention: Twice-weekly strength training (2 days/week)
Number of subjects: 18
Study 15799683 — intervention group
Group type: EXPERIMENTAL
Intervention: Efalizumab 1.0 mg/kg, administered subcutaneously once weekly for 12 weeks
Number of subjects: 0
Study 15799683 — intervention group
Group type: EXPERIMENTAL
Intervention: Efalizumab
Number of subjects: 0
Study 15799683 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12419472 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide (800 microg)
Number of subjects: 9
Study 12419472 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 11160538 — intervention group
Group type: EXPERIMENTAL
Intervention: High fat diet (45% energy)
Number of subjects: 10
Study 11160538 — intervention group
Group type: EXPERIMENTAL
Intervention: Low fat diet (20% energy)
Number of subjects: 10
Study 10211014 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous epidural administration of ropivacaine
Number of subjects: 130
Study 10211014 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural ropivacaine and patient‐controlled analgesia (PCA) with i.v. morphine
Number of subjects: 130
Study 10211014 — intervention group
Group type: COMPARATOR
Intervention: PCA morphine alone
Number of subjects: 130
Study 7948343 — intervention group
Group type: EXPERIMENTAL
Intervention: Cases of basal cell carcinoma (BCC)
Number of subjects: 163
Study 7948343 — intervention group
Group type: COMPARATOR
Intervention: Controls with no known history of BCC or SCC
Number of subjects: 163
Study 7948343 — intervention group
Group type: EXPERIMENTAL
Intervention: Cases of BCC
Number of subjects: 163
Study 3284759 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine
Number of subjects: 15
Study 3284759 — intervention group
Group type: COMPARATOR
Intervention: Methacholine
Number of subjects: 15
Study 3284759 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 15
Study 3284759 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined histamine and methacholine
Number of subjects: 15
Study 28956679 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-implemented intervention delivered via distance video-teleconferencing
Number of subjects: 20
Study 26988921 — intervention group
Group type: EXPERIMENTAL
Intervention: Termination of pregnancy (TOP) for chromosomal abnormality
Number of subjects: 0
Study 26988921 — intervention group
Group type: EXPERIMENTAL
Intervention: Requests for TOPs in French Centres for Perinatal Diagnosis
Number of subjects: 0
Study 26988921 — intervention group
Group type: EXPERIMENTAL
Intervention: TOPs for non-lethal fetal anomalies
Number of subjects: 0
Study 26988921 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental refusal of TOP
Number of subjects: 0
Study 25803245 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra‐articular 20 ml of 0.25% bupivacaine 20 minutes before the start of the operation (preemptive: PE)
Number of subjects: 40
Study 25803245 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra‐articular bupivacaine at the end of the operation with the suction drain opened (DO)
Number of subjects: 40
Study 25803245 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra‐articular bupivacaine at the end of the operation with the drain kept closed for one hour postoperatively (DC)
Number of subjects: 40